Argos Therapeutics, Inc. (NasdaqCM:ARGS) announces review of strategic alternatives. Based on a review of the status of its internal programs, resources and capabilities, Argos plans to explore a wide range of strategic alternatives that may include a potential merger or sale of the Company, among other potential alternatives that could maximize both near and long-term value for our shareholders. Argos Therapeutics has retained Stifel, Nicolaus & Company, Incorporated to serve as its financial advisor in the process. Argos does not have a defined timeline for the exploration of strategic alternatives and is not confirming that the process will result in any strategic alternative being announced or consummated.